Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1 1

Status

Withdrawn 2Terminated 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3

Conditions

Colorectal Neoplasms 2Recurrence 1Neoplasms 1Neoplasm Metastasis 1Gallbladder Neoplasms 1Colonic Neoplasms 1Cholangiocarcinoma 1Carcinoma 1Bile Duct Neoplasms 1

Interventions

Oxaliplatin 780Fluorouracil 638Capecitabine 575Gemcitabine 478Leucovorin 459Bevacizumab 445Irinotecan 444Cisplatin 338Radiotherapy 283Cetuximab 252Paclitaxel 180S 1 (combination) 176pembrolizumab 173Docetaxel 156Drug Therapy 147Nivolumab 146sintilimab 143tislelizumab 131apatinib 131130-nm albumin-bound paclitaxel 128Folfox protocol 121durvalumab 119Albumin-Bound Paclitaxel 117camrelizumab 107lenvatinib 106Panitumumab 106regorafenib 102Surgical Procedures, Operative 102Sorafenib 99Radiation 88

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × galactomannan × Gastrointestinal × Clear all
NCT00388700 2018-02-14

A New Agent GM-CT-01 in Combination With 5-FU, Avastin and Leucovorin in Subjects With Colorectal Cancer

Galectin Therapeutics Inc.

Phase 2 Withdrawn
Gastrointestinal

Colonic Neoplasms, Colorectal Neoplasms

NCT00386516 2017-08-01

Study to Test the Benefit and Safety of GM-CT-01 in Combination With 5-FU to Treat Bile Duct and Gall Bladder Cancer

Galectin Therapeutics Inc.

Phase 2 Withdrawn
Gastrointestinal

Bile Duct Neoplasms, Carcinoma, Gallbladder Neoplasms, Neoplasm Metastasis, Neoplasms, Recurrence, Cholangiocarcinoma

NCT00110721 2012-03-06

GM-CT-01 Plus 5-Fluorouracil as Third- or Fourth-Line Therapy for Metastatic Colorectal Cancer

Galectin Therapeutics Inc.

Phase 2 Terminated
20 enrolled
Gastrointestinal

Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡